APA (7th ed.) Citation

Hamlin, P. A., Musteata, V., Zodelava, M., Park, S. I., Burnett, C., Dabovic, K., . . . Persky, D. O. (2019). Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 134(Supplement_1), 4098. https://doi.org/10.1182/blood-2019-129243

Chicago Style (17th ed.) Citation

Hamlin, Paul A., Vasile Musteata, Mamia Zodelava, Steven I. Park, Christine Burnett, Kristina Dabovic, Eric T. Williams, Jack P. Higgins, and Daniel O. Persky. "Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)." Blood 134, no. Supplement_1 (2019): 4098. https://doi.org/10.1182/blood-2019-129243.

MLA (9th ed.) Citation

Hamlin, Paul A., et al. "Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)." Blood, vol. 134, no. Supplement_1, 2019, p. 4098, https://doi.org/10.1182/blood-2019-129243.